120
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Changes in the intestinal absorption mechanism of icariin in the nanocavities of cyclodextrins

, , , &
Pages 4239-4249 | Published online: 02 Aug 2012

References

  • FrewSESammutSMShoreAFChinese health biotech and the billion-patient marketNature Biotechnol2008261375318183014
  • ZhangGQinLShiYEpimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trialJ Bone Miner Res20072271072107917419678
  • MakarovaMNPozharitskayaONShikovANTesakovaSVMakarovVGTikhonovVPEffect of lipid-based suspension of Epimedium koreanum Nakai extract on sexual behavior in ratsJ Ethnopharmacol2007114341241617890032
  • MengFHLiYBXiongZLJiangZMLiFMOsteoblastic proliferative activity of Epimedium brevicornum MaximPhytomedicine200512318919315830840
  • PanYZhangWYXiaXKongLDEffects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley ratsBiol Pharm Bull200629122399240317142971
  • PanYKongLXiaXZhangWXiaZJiangFAntidepressant-like effect of icariin and its possible mechanism in micePharmacol Biochem Behav200582468669416380159
  • HuangXZhuDLouYA novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cellsEur J Pharmacol20075641–3263617382317
  • MoSFZhouFLvYZHuQHZhangDMKongLDHypouricemic action of selected flavonoids in mice: structure-activity relationshipsBiol Pharm Bull20073081551155617666819
  • LiFGongQHWuQLuYFShiJSIcariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in ratsPharmacol Biochem Behav201096330130520566405
  • XinZCKimEKLinCSEffects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activitiesAsian J Androl200351151812646997
  • ZhangYPXuWLiNLC-MS-MS method for simultaneous determination of icariin and its active metabolite icariside II in human plasmaChromatographia2008683–4245250
  • XuWZhangYYangMLC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasmaJ Pharm Biomed Anal200745466767217706393
  • ChengSQiuFWangSHeJHPLC analysis and pharmacokinetics of icariin in ratsJ Sep Sci20073091307131217623472
  • ChaoJWangHZhaoWZhangMZhangLInvestigation of the inclusion behavior of chlorogenic acid with hydroxypropyl-β-cyclodextrinInt J Biol Macromol201250127728222115718
  • LoftssonTHreinsdottirDMassonMEvaluation of cyclodextrin solubilization of drugsInt J Pharm20053021–2182816099118
  • RajewskiRAStellaVJPharmaceutical applications of cyclodextrins. 2. In vivo drug deliveryJ Pharm Sci19968511114211698923319
  • LiJXiaoHLiJZhongYDrug carrier systems based on water-soluble cationic beta-cyclodextrin polymersInt J Pharm2004278232934215196638
  • LiuJQiuLGaoJJinYPreparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrinInt J Pharm20063121–213714316459034
  • KanoKKitagishiHTanakaSCharacterization of an inclusion complex of 5,10,15,20-tetrakis(4-sulfonatophenyl)-porphinato iron and an O-methylated β-cyclodextrin dimer having a pyridine linker and its related complexes in aqueous solutionJ Incl Phenom Macrocycl Chem2006561–26974
  • GouldSScottRC2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology reviewFood Chem Toxicol200543101451145916018907
  • CastronuovoGNiccoliMThermodynamics of inclusion complexes of natural and modified cyclodextrins with propranolol in aqueous solution at 298 KBioorg Med Chem200614113883388716480882
  • ChallaRAhujaAAliJKharRKCyclodextrins in drug delivery: an updated reviewAAPS Pharm Sci Tech200562E329357
  • BrewsterMELoftssonTThe use of chemically modified cyclodextrins in the development of formulations for chemical delivery systemsPharmazie20025729410111878196
  • DavisMEBrewsterMECyclodextrin-based pharmaceutics: past, present and futureNat Rev Drug Discov20043121023103515573101
  • DucheneDWouessidjeweDPonchelGCyclodextrins and carrier systemsJ Control Release1999621–226326810518659
  • IrieTUekamaKPharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluationJ Pharm Sci19978621471629040088
  • ArimaHYunomaeKHirayamaFUekamaKContribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimusJ Pharmacol Exp Ther2001297254755511303042
  • Meyer dos SantosSWeberCCFrankeCMullerWEEckertGPCholesterol: Coupling between membrane microenvironment and ABC transporter activityBiochem Biophys Res Commun2007354121622117223079
  • FenyvesiFFenyvesiESzenteLP-glycoprotein inhibition by membrane cholesterol modulationEur J Pharm Sci2008344–523624218539442
  • CaiCZhuHChenJOverexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/DoxBiochem Biophys Res Commun2004320386887415240128
  • CalabroMLTommasiniSDonatoPThe rutin/beta-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assaysJ Pharm Biomed Anal20053651019102715620528
  • KunesMSvobodaZKvetinaJHeroutVHerinkJBajgarJIntestinal single-pass in situ perfusion technique in rat: the influence of L-carnitine on absorption of 7-methoxytacrineBiomed Pap Med Fac Univ Palacky Olomouc Czech Repub2005149243343516601805
  • NornooAOZhengHLopesLBJohnson-RestrepoBKannanKReedROral microemulsions of paclitaxel: in situ and pharmacokinetic studiesEur J Pharm Biopharm200971231031718793723
  • BelliSElsenerPMWunderli-AllenspachHKramerSDCholesterol- mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activitiesJ Pharm Sci20099851905191818937360
  • HiguchiTConnorsKPhase solubility techniquesAdvances in Analytical Chemistry and Instrumentation19657117212
  • YangHParniakMAIsaacsCEHillierSLRohanLCCharacterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781AAPS J200810460661319089644
  • Badr-EldinSMElkheshenSAGhorabMMInclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluationEur J Pharm Biopharm200870381982718655829
  • CappelloBDi MaioCIervolinoMMiroAImprovement of solubility and stability of valsartan by hydroxypropyl-beta-cyclodextrinJ Incl Phenom Macrocycl Chem2006543–4289294
  • SchneiderHJHacketFRudigerVIkedaHNMR studies of cyclodextrins and cyclodextrin complexesChem Rev19989851755178611848948
  • de AraujoMVVieiraEKSilva LazaroGSulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modelingBioorg Med Chem200816105788579418434167
  • JullianCOrosteguisTPerez-CruzFSanchezPMendizabalFOlea-AzarCComplexation of morin with three kinds of cyclodextrin. A thermodynamic and reactivity studySpectrochim Acta A Mol Biomol Spectrosc200871126927518262835
  • SalphatiLChildersKPanLTsutsuiKTakahashiLEvaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in manJ Pharm Pharmacol20015371007101311480535
  • EckfordPDSharomFJABC efflux pump-based resistance to chemotherapy drugsChem Rev200910972989301119583429
  • ZhouSLimLYChowbayBHerbal modulation of P-glycoproteinDrug Metab Rev20043615710415072439
  • TeodoriEDeiSScapecchiSGualtieriFThe medicinal chemistry of multidrug resistance (MDR) reversing drugsFarmaco200257538541512058813
  • DaiFLiuWEnhanced gene transfection and serum stability of polyplexes by PDMAEMA-polysulfobetaine diblock copolymersBiomaterials201132262863820888634
  • CollnotEMBaldesCWempeMFMechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidityMol Pharm20074346547417367162